Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors

• Glavni autori: Junichi Yoshida (Autor), Kenichiro Shiraishi (Autor), Tetsuro Tamura (Autor), Kazuhiro Otani (Autor), Tetsuya Kikuchi (Autor), Akiko Mataga (Autor), Takako Ueno (Autor), Masao Tanaka (Autor)
• Format: Knjiga
• Izdano: BMC, 2022-01-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

Abstract Background Casirivimab-imdevimab has been developed to neutralize SARS-CoV-2. The global clinical trials in outpatients documented several adverse effects (AE), which mandate caution in Japan where part of patients return home. To investigate post-infusion clinical events and their risk fac...